Latest news with #WinselowTucker
India Today
15-05-2025
- Health
- India Today
Tirzepatide outperforms semaglutide in clinical trial with faster weight loss
A major trial shows tirzepatide, recently launched in India, helps people lose more weight and shrink their waistlines faster than semaglutide.A new study has found that tirzepatide, a weight-loss injection introduced in India this March, is more effective than semaglutide, a popular obesity drug already available in the a clinical trial that ran for 72 weeks, people who took tirzepatide lost about 23 kg on average, while those on semaglutide lost around 15 Both drugs were given once a week through injections, and participants also followed a controlled diet and exercised research, published in The New England Journal of Medicine, showed that tirzepatide also helped people reduce more belly fat, with an average waistline drop of 7.2 inches, compared to 5.1 inches with is sold under the brand name Mounjaro, developed by US-based company Eli Lilly. It's a dual-action drug (dual GIP and GLP-1 receptor agonist), which means it targets two hormones that control appetite and blood sugar. This helps people feel full sooner and eat less. Tirzepatide is sold under the brand name Mounjaro, developed by US-based company Eli Lilly. () advertisementSemaglutide, made by Danish drugmaker Novo Nordisk, works in a similar way but acts on just one hormone (mono GLP-1 receptor agonist). A lower-dose pill version of semaglutide (Rybelsus) has been available in India since 2022, but the more powerful injectables (Ozempic and Wegovy) have not yet launched Nordisk has confirmed it plans to bring Wegovy to India later this the study, 65% of people who took tirzepatide lost at least 15% of their body weight, compared to 40% of those on semaglutide.'It's a big step forward in treating obesity, which is a serious long-term health condition,' said Winselow Tucker, President and General Manager of Lilly trial involved 751 participants from the US and Puerto Rico, all of whom were either obese (BMI over 30) or overweight (BMI 25–30) with other health issues like high blood pressure, sleep apnea, or heart disease, but none had diabetes. Everyone was given diet and exercise advice, in addition to the weekly EFFECTS AND SAFETYLike many weight-loss drugs, both tirzepatide and semaglutide caused mild to moderate side effects, mainly stomach-related issues like nausea, vomiting, and bloating.A small number of people stopped taking the drugs because of side effects, about 6% on tirzepatide and 8% on researchers noted that while the trial wasn't designed to directly compare the safety of both drugs, the findings were consistent with earlier tirzepatide and semaglutide are prescription-only and should only be taken under a doctor's supervision. They are not meant for short-term or cosmetic use, and regular monitoring is required to manage side effects. You May Also Like
The Print
13-05-2025
- Health
- The Print
Mounjaro vs Wegovy: Guess which obesity drug outperformed the other by a mile in head-to-head trial
New Delhi: A head-to-head clinical trial comparing two globally popular obesity drugs—tirzepatide and semaglutide—revealed that the former, launched in India in March, proved significantly more effective than the latter in reducing both weight and waist circumference after 72 weeks of treatment. Tirzepatide, developed by US-based pharmaceutical giant Eli Lilly and Company and sold under the brand name Mounjaro, had already made a global impact prior to its Indian debut on 20 March. A less potent version of semaglutide, by Danish drugmaker Novo Nordisk, in pill form under the brand name Rybelsus, has been available in India since January 2022. However, Ozempic and Wegovy—the injectables in higher dosage strengths—have yet to be rolled out in the country. Show Full Article Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended alongside a controlled diet and regular physical activity. Lilly announced Monday that complete data from its phase 3b, open-label clinical trial (a trial in which both researchers and participants are not kept in the dark about which treatment is being administered), SURMOUNT-5, demonstrated the safety and efficacy of tirzepatide in adults with obesity (BMI of 30 or higher) or those overweight (BMI between 25 and 29.9) with at least one associated medical condition—excluding diabetes. According to Lilly, participants administered tirzepatide saw an average weight reduction of 20.2 percent, while those on semaglutide experienced a 13.7 percent loss—indicating a 47 percent greater relative weight loss for the former, based on the treatment-regimen estimand at 72 weeks. The findings, published in The New England Journal of Medicine Sunday, noted that participants on tirzepatide lost an average of 22.8 kg, while those on semaglutide shed around 15 kg. Tirzepatide also outperformed semaglutide in all weight reduction benchmarks: 64.6 percent of individuals on tirzepatide achieved at least a 15 percent body weight loss compared to 40.1 percent on semaglutide. In terms of waistline impact, those on tirzepatide recorded an average reduction of 7.2 inches, whereas semaglutide users saw a decrease of 5.1 inches. 'Obesity is a chronic disease that requires comprehensive management, and Lilly is committed to supporting people with obesity and enhancing the standard of care in obesity management in India,' said Winselow Tucker, company president and general manager for India. He added that results from the SURMOUNT-5 trial provide robust evidence supporting tirzepatide as an effective option for obesity management in the country. Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, while semaglutide functions as a mono GLP-1 receptor agonist. Both GIP and GLP-1 are natural incretin hormones (gut hormones that stimulate a decrease in blood glucose levels) found in brain regions that regulate appetite. These agents work by lowering caloric intake, primarily by influencing appetite control mechanisms. In response to a query by ThePrint last week, Novo Nordisk confirmed it would launch Wegovy in India this year, which delivers the full therapeutic strengths of semaglutide for complete obesity and weight management. 'It also provides remarkable cardiovascular benefits and more, making it an impactful option for obesity care,' Novo Nordisk said. According to the largest-ever Indian obesity survey conducted jointly by the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation (MDRF) in 2023, 254 million Indians—or 28.6 percent of the population—had generalised obesity. The same survey estimated that 351 million people, or 39.5 percent of the population, were affected by abdominal obesity. Over recent decades, evidence linking a high BMI to a number of non-communicable diseases—including hypertension, diabetes, dyslipidaemia (abnormal levels of lipids or lipoproteins in the blood), and cancer—has grown, with obesity now widely recognised as a leading contributor to mortality. Also Read: New subtype of diabetes found in India could change how rare forms of disease are treated Tirzepatide also slightly safer than semaglutide The SURMOUNT-5 trial ran for 72 weeks and was conducted across multiple centres. It was a randomised, open-label, phase 3b study comparing the efficacy and safety of tirzepatide with semaglutide in adults who were obese or overweight and had one or more associated comorbidities: hypertension, dyslipidaemia, obstructive sleep apnoea (sleep disorder in which there are repeated pauses in breathing while sleeping), or cardiovascular disease—but without diabetes. All participants received counselling on reducing caloric intake and increasing physical activity. A total of 751 participants across the US and Puerto Rico were randomised in a 1:1 ratio to receive either tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg), depending on their maximum tolerated dose. Among those receiving tirzepatide, 89.3 percent were administered at least one dose of 15 mg. For semaglutide, 92.8 percent received at least one dose of 2.4 mg. Lilly stated that tirzepatide's safety profile in this trial aligned with findings from previous SURMOUNT studies. Most adverse events reported were gastrointestinal in nature and were largely mild to moderate in severity. During the trial, 6.1 percent of participants on tirzepatide discontinued the drug due to adverse events, compared to eight percent of those taking semaglutide. 'However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide,' Eli Lilly clarified in a statement. These classes of anti-obesity and diabetes medications have been associated with side effects such as nausea, vomiting, and bloating. In rare instances, the drugs have been linked to gastroparesis, a condition in which intestinal muscles fail to move food efficiently, resulting in delayed digestion. A senior obesity researcher at the All India Institute of Medical Sciences (AIIMS), Delhi, who wished not to be named, told ThePrint that the new findings marked a turning point in the treatment of obesity. 'But it should be remembered that these medicines should only be taken under expert guidance and supervision,' he stressed. (Edited by Radifah Kabir) Also Read: Pune-based firm receives major international grant to accelerate development of Nipah virus vaccine
&w=3840&q=100)
Business Standard
12-05-2025
- Health
- Business Standard
Eli Lilly's tirzepatide shows superior weight loss to Novo's semaglutide
US-based pharmaceutical company Eli Lilly has announced results from a head-to-head clinical trial showing that its obesity drug tirzepatide (sold as Mounjaro) led to greater weight loss in adults than semaglutide (sold as Wegovy). The detailed findings from the 72-week phase 3b SURMOUNT-5 trial were presented at the European Congress on Obesity and published in The New England Journal of Medicine. Participants using tirzepatide lost an average of 20.2 per cent of their body weight, or 22.8 kg, compared to 13.7 per cent, or 15.0 kg, with semaglutide. The trial included 751 adults with obesity or overweight with weight-related health conditions, but without diabetes. Tirzepatide also performed better on all secondary goals. Nearly 65 per cent of participants taking tirzepatide lost at least 15 per cent of their body weight, compared to 40 per cent on semaglutide. In terms of waist circumference, the average reduction was 18.4 cm with tirzepatide and 13.0 cm with semaglutide. The trial was not designed to directly compare the safety profiles of the two drugs. However, gastrointestinal issues were the most common side effects in both groups. About 6.1 per cent of participants on tirzepatide stopped treatment due to side effects, compared to 8.0 per cent on semaglutide. In India, Eli Lilly markets tirzepatide as Mounjaro for type 2 diabetes, and is positioning it for use in obesity care as well. 'The results from SURMOUNT-5 provide evidence for tirzepatide as a treatment option for obesity in India,' said Winselow Tucker, President and GM, Eli Lilly India. Both medications are part of a newer class of drugs that act on hormone receptors involved in appetite regulation. Tirzepatide targets two receptors (GIP and GLP-1), while semaglutide targets only one (GLP-1). Participants in the study were also advised on a reduced-calorie diet and physical activity. Eli Lilly's tirzepatide is sold as Zepbound in the US for obesity, and as Mounjaro for type 2 diabetes. Semaglutide is marketed by Novo Nordisk under Wegovy for obesity and Ozempic for type 2 diabetes.
&w=3840&q=100)
Business Standard
12-05-2025
- Health
- Business Standard
Lilly's tirzepatide shows superior weight loss to Novo's semaglutide
US-based pharmaceutical company Eli Lilly has announced results from a head-to-head clinical trial showing that its obesity drug tirzepatide (sold as Mounjaro) led to greater weight loss in adults than semaglutide (sold as Wegovy). The detailed findings from the 72-week phase 3b SURMOUNT-5 trial were presented at the European Congress on Obesity and published in The New England Journal of Medicine. Participants using tirzepatide lost an average of 20.2 per cent of their body weight, or 22.8 kg, compared to 13.7 per cent, or 15.0 kg, with semaglutide. The trial included 751 adults with obesity or overweight with weight-related health conditions, but without diabetes. Tirzepatide also performed better on all secondary goals. Nearly 65 per cent of participants taking tirzepatide lost at least 15 per cent of their body weight, compared to 40 per cent on semaglutide. In terms of waist circumference, the average reduction was 18.4 cm with tirzepatide and 13.0 cm with semaglutide. The trial was not designed to directly compare the safety profiles of the two drugs. However, gastrointestinal issues were the most common side effects in both groups. About 6.1 per cent of participants on tirzepatide stopped treatment due to side effects, compared to 8.0 per cent on semaglutide. In India, Eli Lilly markets tirzepatide as Mounjaro for type 2 diabetes, and is positioning it for use in obesity care as well. 'The results from SURMOUNT-5 provide evidence for tirzepatide as a treatment option for obesity in India,' said Winselow Tucker, President and GM, Eli Lilly India. Both medications are part of a newer class of drugs that act on hormone receptors involved in appetite regulation. Tirzepatide targets two receptors (GIP and GLP-1), while semaglutide targets only one (GLP-1). Participants in the study were also advised on a reduced-calorie diet and physical activity. Eli Lilly's tirzepatide is sold as Zepbound in the US for obesity, and as Mounjaro for type 2 diabetes. Semaglutide is marketed by Novo Nordisk under Wegovy for obesity and Ozempic for type 2 diabetes. Ongoing studies are assessing tirzepatide's effect on conditions such as kidney disease and sleep apnoea in patients with obesity.
Al Arabiya
20-03-2025
- Health
- Al Arabiya
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator green light
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from the country's drug regulator, it said on Thursday. Global demand for Lilly's diabetes and weight-loss drugs has soared, with the launch presenting a big market opportunity for the US-based drug company as India, the world's most populous country, is seeing increasing rates of obesity and diabetes. 'The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India,' said President and General Manager Winselow Tucker at Lilly India. India has about 101 million people living with diabetes, and obesity—a chronic, relapsing disease—is a major risk factor for diabetes, Lilly said. Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both diabetes and weight loss. It is sold as Zepbound for obesity in the US. CEO David Ricks told Reuters in February last year that Lilly expects to launch Mounjaro in India as early as 2025. Analysts have projected global obesity drug sales to reach $150 billion a year by the early 2030s.
